Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria
Life · 21.12.2023 · 14 (1) · 19
DOI: 10.3390/life14010019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 21.12.2023. Verfasst von Elin Storjord und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nordland Hospital Trust, 8092 Bodø, Norway. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nordland Hospital Trust, Northern Norway Regional Health Authority, Somatic Research Fund at Nordland Hospital Trust and the Northern Norway Regional Health Authorities.
Abstract (Originalsprache)
Acute intermittent porphyria (AIP) is an inherited metabolic disorder associated with complications including kidney failure and hepatocellular carcinoma, probably caused by elevations in the porphyrin precursors porphobilinogen (PBG) and delta-aminolevulinic acid (ALA). This study explored differences in modern biomarkers for renal and hepatic damage between AIP patients and controls. Urine PBG testing, kidney injury panels, and liver injury panels, including both routine and modern biomarkers, were performed on plasma and urine samples from AIP cases and matched controls (50 and 48 matched pairs, respectively). Regarding the participants’ plasma, the AIP cases had elevated kidney injury marker-1 (KIM-1, p = 0.0002), fatty acid-binding protein-1 (FABP-1, p = 0.04), and α-glutathione S-transferase (α-GST, p = 0.001) compared to the matched controls. The AIP cases with high PBG had increased FABP-1 levels in their plasma and urine compared to those with low PBG. In the AIP cases, KIM-1 correlated positively with PBG, CXCL10, CCL2, and TCC, and the liver marker α-GST correlated positively with IL-13, CCL2, and CCL4 (all p < 0.05). In conclusion, KIM-1, FABP-1, and α-GST could represent potential early indicators of renal and hepatic damage in AIP, demonstrating associations with porphyrin precursors and inflammatory markers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Nordland Hospital Trust, 8092 Bodø, Norway.
- Hepatology Division, Department of Upper GI Diseases, Porphyria Centre Sweden, Karolinska Institute and Karolinska University Hospital, 14186 Stockholm, Sweden.
- Research Laboratory, Nordland Hospital Trust, 8092 Bodø, Norway.
- Department of Nephrology, Nordland Hospital Trust, 8092 Bodø, Norway.
- Department of Clinical Medicine, UiT-The Arctic University of Norway, 9019 Tromsø, Norway.
- Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
ORCID-Profile: Staffan Wahlin, Bård Ove Karlsen, Randolf I Hardersen, Ole-Lars Brekke
Förderung
- Nordland Hospital Trust
- Northern Norway Regional Health Authority
- Somatic Research Fund at Nordland Hospital Trust and the Northern Norway Regional Health Authorities
Zitieren
APA
Storjord, E., Wahlin, S., Karlsen, B. O., Hardersen, R. I., Dickey, A. K., Ludviksen, J. K., & Brekke, O. L. (2023). Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria. Life, 14(1), 19. https://doi.org/10.3390/life14010019
Vancouver
Storjord E, Wahlin S, Karlsen BO, Hardersen RI, Dickey AK, Ludviksen JK, et al. Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria. Life. 2023;14(1):19. doi:10.3390/life14010019
BibTeX
@article{Storjord2023,
author = {Storjord, Elin and Wahlin, Staffan and Karlsen, Bård Ove and Hardersen, Randolf I and Dickey, Amy K and Ludviksen, Judith K and Brekke, Ole-Lars},
title = {Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria},
journal = {Life},
year = {2023},
volume = {14},
number = {1},
pages = {19},
doi = {10.3390/life14010019}
}
EUVIMED